Amgen has submitted a supplemental Biologics License Application (sBLA) to the FDA to expand the indication for denosumab (XGEVA) its RANK ligand inhibitor to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. Although some doctors have already begun to use Xgeva in men with advanced prostate cancer, it is [...]
There is some good news; the New York State Legislature has passed the Oral Chemotherapy Equity Bill. However, before this bill can become law we have to have Governor Cuomo sign it, we need all of our New York Residents to contact the governor and ask that he signs it. […]
Amgen has submitted a supplemental Biologics License Application (sBLA) to the FDA to expand the indication for denosumab (XGEVA) its RANK ligand inhibitor to treat men with castrate-resistant prostate cancer to reduce the risk of developing bone metastases. If approved, denosumab would be the first therapy licensed to prevent or delay the spread of cancer [...]
Regeneron Pharmaceuticals, Inc. announced that the Phase 3 VENICE clinical trial evaluating the investigational agent Zaltrap (aflibercept) in the first-line treatment of men with castrate resistant prostate cancer will continue to completion as planned. They have not been asked to make any modifications due to efficacy or to safety concerns. This decision is based on [...]
My recent Letter to the Editor of the New York Times in response to the Op-Ed piece decrying the cost of cancer treatments: Your recent editorial about the high cost of cancer drugs missed a number of very significant points which must be considered. Yes, newly developed cancer drugs are expensive, but when treatments like [...]